Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYXBiotechnology
-$0.02 today
- Market cap
- $80.25M
- Beta
- 0.00
- P/E (TTM)
- -16.7
- EPS (TTM)
- -$0.14
Volume 0.02M
Average 0.34M
PLYX Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$3.08M, compared with -$4.16M a year earlier.
Context
- Net debt amounted to 87.9% of total assets at the end of Q1 FY2026, down 5.8 pp from a year earlier.
- Net debt increased in 0 of the last 2 fiscal years.
- FY2025 was the lowest annual figure in the 3 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +26.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (5.14M) USD
- Year-over-year change
- -11.3%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.14M) | -11.3% |
| FY2024 | 2024-12-31 | (4.62M) | -3767.5% |
| FY2023 | 2023-12-31 | 126K | — |
Net Debt vs competitors
How PLYX compares with its peers on the latest reported figures
- PLYX's Mar 2026 net debt of -$3.08M is the 2nd highest of the 8 companies compared; the peer median is -$46.92M.
- Its year-over-year change of +26.0% is the 4th highest of 8, against a peer median of -23.9%.
- Net debt amounts to 87.9% of total assets for PLYX, versus a peer median of 21.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $20.71M | +772.9% | +225.9% | 14.2% | |
PLYXPolaryx Therapeutics, Inc. Common Stock | Mar 2026 | -$3.08M | +26.0% | — | 87.9% |
KLRSKalaris Therapeutics Inc | Mar 2026 | -$33.02M | +67.3% | — | 30.1% |
| Mar 2026 | -$41.92M | +33.7% | — | 12.0% | |
| Mar 2026 | -$46.92M | -79.3% | — | 21.1% | |
| Mar 2026 | -$53.49M | -167.6% | — | 61.1% | |
| Mar 2026 | -$54.41M | -23.9% | — | 17.0% | |
| Mar 2026 | -$187.62M | -3241.9% | — | 94.2% | |
| Peer median (excluding PLYX) | -$46.92M | -23.9% | +225.9% | 21.1% | |
Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Cash & Equivalents | 2K | 4.62M | 5.14M |
| Short-term Investments | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 27K |
| Total Current Assets | 2.32M | 5M | 5.17M |
| Property, Plant & Equipment (Net) | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 250K |
| Other Non-current Assets | 0 | 0 | 0 |
| Total Non-current Assets | 0 | 0 | 250K |
| Total Assets | 2.32M | 5M | 5.42M |
| Account Payables | 473K | 72K | 470K |
| Short-term Debt | 128K | 0 | 0 |
| Tax Payables | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 |
| Other Current Liabilities | 1K | 1K | 114K |
| Total Current Liabilities | 1.04M | 289K | 605K |
| Long-term Debt | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 250K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 0 | 250K |
| Total Liabilities | 1.04M | 289K | 855K |
| Common Stock | 4K | 16K | 5K |
| Retained Earnings | (60.29M) | (90.65M) | (99.64M) |
| Accumulated OCI | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| Total Equity | 1.28M | 4.71M | 4.57M |
| Total Debt | 128K | 0 | 0 |
| Net Debt | 126K | (4.62M) | (5.14M) |
Polaryx Therapeutics, Inc. Common Stock
NASDAQ:PLYX
Intrinsic Alpha fair value
Locked
Current Price
$1.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.